Amyloid in the cardiovascular system: A review

Journal of Clinical Pathology

Volumn 58, Issue 2, 2005, Pages 125-133

  Kholova I ^a,b   Niessen, H W M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ALPHA INTERFERON; AMYLOID; DEXAMETHASONE; DIURETIC AGENT; MELPHALAN; PREDNISONE; VINCRISTINE;

AGE; AMYLOIDOSIS; AORTA DISEASE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; GENETIC DISORDER; GERIATRIC DISORDER; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART ATRIUM AMYLOIDOSIS; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER TRANSPLANTATION; MORPHOLOGY; NOMENCLATURE; NON INVASIVE MEASUREMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENILE AORTA AMYLOIDOSIS; SYSTEMIC DISEASE; SYSTEMIC SENILE AMYLOIDOSIS; VALVULAR HEART DISEASE; VASCULAR DISEASE;

AGING; ALGORITHMS; AMYLOIDOSIS; CARDIOVASCULAR DISEASES; DIAGNOSTIC ERRORS; HEART DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; MYOCARDIUM; PROGNOSIS;

EID: 13244254047     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.017293     Document Type: Review

References (143)

1. Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses. N Engl J Med 1980;302:1283-92.
2. Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses. N Engl J Med 1980;302:1333-43.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
4. Westermark P, Araki S, Benson MD, et al. Nomenclature of amyloid fibril proteins. Part 1. Amyloid 1999;6:63-6.
5. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature-2002. Amyloid 2002;9:197-200.
6. WHO-IUIS Nomenclature Sub-Committee. Nomenclature of amyloid and amyloidosis. Bull World Health Organ 1993;71:105-12.
7. Husby G, Stenstad T, Magnus JH, et al. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis or systemic amyloidosis. Clin Immunol Immunopathol 1994;70:2-9.
8. Kawahara E, Shiroo M, Nakanishi I, et al. The role of fibronectin in the development of experimental amyloidosis: evidence of immunohistochemical codistribution and binding property with serum amyloid protein A. Am J Pathol 1989;134:1305-14.
9. Lyon AW, Narindrasorasak S, Young ID, et al. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 1991;64:785-90.
10. Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-22.
11. Buxbaum JN. Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases. Trends Biochem Sci 2003;28:585-92.
12. Ando Y, Suhr O, El-Salhy M. Oxidative stress and amyloidosis. Histol Histopathol 1998;13:845-50.
13. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
14. Andersson K, Olofsson A, Nielsen EH, et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002;294:309-14.
15. Loo DT, Agata C, Pike CJ. Apoptosis is induced by β-amyloid in cultured nervous system neurons. Proc Natl Acad Sci U S A 1993;90:7951-5.
16. Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med 1997;337:898-909.
17. Kyle RA, Bayrd ED. Amyloidosis: a review of 236 cases. Medicine 1975;54:271-91.
18. Pascali E. Diagnosis and treatment of primary amyloidosis. Crit Rev Oncol Hematol 1995;19:149-81.
19. Browning MJ, Banks RA, Tribe CR, et al. Ten years experience of an amyloid clinic-a clinicopathologic survey. Q J Med 1985;54:213-27.
20. Kingman A, Pereira NL. Cardiac amyloidosis. J S C Med Assoc 2001;97:201-6.
21. Varga J, Wohlgethan JR. The clinical and biochemical spectrum of hereditary amyloidosis. Semin Arthritis Rheum 1988;18:14-28.
22. Sohar E, Pras M, Heller J, et al. Genetics of familial Mediterranean fever. Arch Intern Med 1961;107:529-38.
23. Gorevic PD, Rodrigues MM. Ocular amyloidosis. Am J Ophthalmol 1994;117:529-32.
24. Thomas PK. Genetic factors in amyloidosis. J Med Genet 1975;12:317-26.
25. Cornwell GG III, Westermark P. Senile amyloidosis: a protean manifestation of the aging process. J Clin Pathol 1980;33:1146-52.
26. Cornwell GG III, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation. Am J Med 1983;75:618-23.
27. Cornwell GG III, Johnson KH, Westermark P. The age related amyloids: a growing family of unique biochemical substances. J Clin Pathol 1995;48:984-9.
28. Westermark P, Sletten K, Johanson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990;87:2843-5.
29. Steiner I. The prevalence of isolated atrial amyloid. J Pathol 1987;153:395-8.
30. Lie JT. Pathology of amyloidosis and amyloid heart disease. Appl Pathol 1984;2:341-56.
31. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiological abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 1997;30:1046-51.
32. Cantwell R, Aviles R, Bjornsson J. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol 2002;25:33-7.
33. Wright JR, Calkins E. Clinical-pathologic differentiation of common amyloid syndromes. Medicine (Baltimore) 1981;60:429-48.
34. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (L) amyloidosis with heart involvement. Q J Med 1998;91:141-57.
35. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999;13:1211-33.
36. O'Hara CJ, Falk RH. The diagnosis and typing of cardiac amyloidosis. Amyloid 2003;10:127-9.
37. Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol 2004;16:67-75.
38. Klein AL, Oh JK, Miller FA, et al. Two-dimensional and Doppler echocardiographic assessment of infiltrative cardiomyopothy. J Am Soc Echocardiogr 1988;1:48-59.
39. Fattori R, Rocchi G, Celleti F, et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am J Heart 1998;136:824-30.
40. Shikano M, Kushimoto H, Hasegawa H, et al. Usefulness of serum hepatocyte growth factor for the diagnosis of amyloidosis. Intern Med 2000;39:715-19.
41. Ando Y, Haraoka K, Terazaki H, et al. A novel tool for detecting amyloid deposits in systemic amyloidosis in vitro and in vivo. Lab Invest 2003;83:1751-9.
42. Westermark P, Stenkvist P. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 1973;132:522-3.
43. Gertz MA. Diagnosing primary amyloidosis. Mayo Clin Proc 2002;77:1278-9.
44. Kuroda T, Tanabe N, Sakatsume M, et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol 2002;21:123-8.
45. Masouye I. Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. Am J Dermatopathol 1997;19:41-5.
46. Orfilo C, Giraud P, Modesto A, et al. Abdominal fat tissue aspirate in human amyloidosis: light, electron, and immunofluorescence microscopic studies. Hum Pathol 1986;17:366-9.
47. Röcken C, Sletten K. Amyloid in surgical pathology. Virchows Arch 2003;443:3-16.
48. Gafni J, Sohar E. Rectal biopsy for the diagnosis of amyloidosis. Am J Med Sci 1960;240:332-6.
49. Fatihi E, Ramdani B, Fadel H, et al. Prevalence of subcutaneous, labial, and rectal amyloidosis in patients with renal amyloidosis. Nephrologie 2000;21:19-21.
50. Kyle RA, Spencer RJ, Dahlin DC. Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Am J Med Sci 1966;251:501-6.
51. Gertz MA, Lacy MQ, Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 2002;61:1-9.
52. Schena FP, Pannarale G, Carbonaro MC. Clinical and therapeutic aspects of renal amyloidosis. Nephrol Dial Transplant 1996;11(suppl 9):63-8.
53. Rajani B, Rajani V, Prayson RA. Peripheral nerve amyloidosis in sural nerve biopsies-a clinicopathologic analysis of 13 cases. Arch Pathol Lab Med 2000;124:114-18.
54. Prayson RA. Amyloid myopathy: clinicopathologic study of 16 cases. Hum Pathol 1998;29:463-8.
55. Kaplan B, Shtrasburg S, Pras M. Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003;56:86-90.
56. Murphy CL, Eulitz M, Hrncic R, et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001;116:135-42.
57. Frenzel H, Schwartzkopff, Kuhn H, et al. Cardiac amyloid deposits in endomyocardial biopsies. Light microscopic, ultrastructural, and immunohistochemical studies. Am J Clin Pathol 1986;85:674-80.
58. Crotty TB, Li C-Y, Edwards WD, et al. Amyloidosis and endomyocardial biopsy: correlation and extent and pattern of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol 1995;4:39-42.
59. Pellikka PA, Holmes DR, Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 1988;148:662-6.
60. Olson LJ, Gertz MA, Edwards WD, et al. Senile cardiac amyloidosis with myocardial dysfunction: diagnosis by endomyocardial biopsy and immunohistochemistry. N Engl J Med 1987;317:738-42.
61. Arbustini E, Merlini G, Gavazzi A, et al. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. Am Heart J 1995;130:528-36.
62. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001;104:2996-3007.
63. Scully RE, Mark EJ, McNeely BU. Case records of the Massachusetts General Hospital. Case 30-1982. N Engl J Med 1982;307:298-303.
64. McCarthy RE, Kasper EK. A review of the amyloidoses that infiltrate the heart. Clin Cardiol 1998;21:547-52.
65. Suhr OB, Hastrup Svendsen I, Andersson R, et al. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003;254:225-35.
66. Linke RP. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch 2000;436:439-48.
67. Bancroft JD, Cook HC. Amyloid. In: Manual of histological techniques, 1st ed. Edinburgh: Churchill Livingstone, 1984:87-99.
68. Eliot RS, McGee HJ, Blount SG Jr. Cardiac amyloidosis. Circulation 1961;23:613-22.
69. Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 1983;52:137-46.
70. Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984;59:547-55.
71. Bennhold H. Eine spezifische Amyloidfärburg mit Kongorot. Munch Med Wochenschr 1920;69:1537-49.
72. Pearse AGE. Amyloids: the β-fibrilloses. In: Histochemistry: theoretical and applied, Vol. II, 4 ed. Boston: Little Brown and Co, 1985:576-82.
73. Wolman M, Bubis JJ. The cause of the green polarization color of amyloid stained with Congo red. Histochemie 1965;4:351-9.
74. Puchtler H, Waldrop FS, Meloan SN. A review of light, polarization and fluorescence microscopic methods for amyloid. Appl Pathol 1985;3:5-17.
75. Westermork GP, Johnson KH, Westermark P. Staining methods for identification of amyloid tissue. Methods Enzymol 1999;309:3-25.
76. Nippoldt TB, Edwards WD, Holmes DR Jr, et al. Right ventricular endomyocardial biopsy: clinicopathologic correlates in 100 consecutive patients. Mayo Clin Proc 1982;57:407-18.
77. Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol 1979;44:413-17.
78. Ridolfi BL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis: clinical and pathologic features of 23 patients. Am J Med 1977;62:677-86.
79. Kisilevsky R. Amyloid and amyloidoses: differences, common themes, and practical considerations. Mod Pathol 1991;4:514-18.
80. Röcken C, Schwotzer E, Linke RP, et al. The classification of amyloid deposits in clinicopathological practice. Histopathology 1996;29:325-35.
81. Röcken C, Peters B, Juenemann G, et al. Atrial amyloidosis. An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-7.
82. Arbustini E, Morbini P, Verga L, et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 1997;4:157-70.
83. Strege RJ, Saeger W, Linke RP. Diagnosis and immunohistochemical classification of systemic amyloidoses. Report of 43 cases in an unselected autopsy series. Virchows Arch 1998;433:19-27.
84. Arbustini E, Verga L, Concorde M, et al. Electron and immuno-electro microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108-14.
85. Cohen AS, Calkins E. Electron microscopic observations on fibrous component in amyloid of diverse origin. Nature 1959;183:1202-3.
86. Stevens FJ, Myatt EA, Chang CH, et al. A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry 1995;34:10697-702.
87. Mudhar HS, Wagner BE, Suvarna SK. Electron microscopy of myocardial tissue. A nine year review. J Clin Pathol 2001;54:321-5.
88. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.
89. Gertz MA, Kyle RA. Primary systemic amyloidosis-a diagnostic primer. Mayo Clin Proc 1989;64:1505-19.
90. Yamano S, Motomiya K, Akai Y, et al. Primary systemic amyloidosis presenting as angina pectoris due to intramyocardial coronary artery involvement: a case report. Heart Vessels 2002;16:157-60.
91. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000;109:181-8.
92. Ishikawa Y, Ishii T, Masuda S, et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int 1996;46:189-94.
93. Goffin Y. Microscopic amyloid deposits in the heart valves: a common local complication of chronic damage and scarring. J Clin Pathol 1980;33:262-8.
94. Sequeira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981;63:188-96.
95. Daubert JP, Gaede J, Cohen HJ. A fatal case of constrictive pericarditis due to a marked, selective pericardial accumulation of amyloid. Am J Med 1993;94:335-40.
96. Nakata T, Shimamoto K. Cardiac denervation in amyloid polyneuropathy. Lancet 2003;361:1181.
97. Jennette JC, Sheps DS, McNeill DD. Exclusively vascular systemic amyloidosis with visceral ischemia. Arch Pathol Lab Med 1982;106:323-7.
98. Ohashi K, Takagawa R, Hara M. Visceral organ involvement and extracellular matrix changes in β2-microglobulin amyloidosis-a comparative study with systemic AA and AL amyloidosis. Virchows Arch 1997;430:479-87.
99. 2-microglobulin: a new form of amyloid protein associated with chronic haemodialysis. Kidney Int 1986;30:385-90.
100. McAdam KPWJ, Sipe JD. Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J Exp Med 1976;144:1121-7.
101. Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta 1995;1270:81-6.
102. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 1991;79:246-56.
103. Beydoun SR, Rison RA, Commins D. Secondary amyloidosis as a life-ending event in multifocal motor neuropathy. Muscle Nerve 2001;24:1396-402.
104. Ahmed Q, Chung-Park M, Mustafa K, et al. Psoriatic spondyloarthropathy with secondary amyloidosis. J Rheumatol 1996;23:1107-10.
105. Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler electrocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996;77:313-15.
106. Stather D, Ford S, Kisilevsky R. Sarcoid, amyloid, and acute myocardial failure. Mod Pathol 1998;11:901-4.
107. Cooper JH. Localised dystrophic amyloidosis of heart valves. Hum Pathol 1983;14:649-53.
108. Ladefoged C, Rohr N. Amyloid deposits in aortic and mitral valves. A clinicopathological investigation of material from 100 consecutive heart valve operations. Virch Arch A Pathol Anat Histopathol 1984;404:301-12.
109. Looi LM. Isolated atrial amyloidosis: a clinicopathologic study indicating increased prevalence in chronic heart disease. Hum Pathol 1993;24:602-7.
110. Johansson B, Werstedt C, Westermark P. Atrial natriuretic peptide deposited as atrial amyloid fibrils. Biochem Biophys Res Commun 1987;148:1087-92.
111. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 1988;63:552-64.
112. Sawabe M, Hamamatsu A, Ito T, et al. Early pathogenesis of cardiac amyloid deposition in senile systemic amyloidosis: close relationship between amyloid deposits and the basement membranes of myocardial cells. Virchows Arch 2003;442:252-7.
113. Allensworth DC, Rice GJ, Lowe GJ. Persistent atrial standstill in a family with myocardial disease. Am J Med 1969;47:775-84.
114. Benson MD, Wallace MR, Teyada E, et al. Hereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy. Arthritis Rheum 1987;30:195-200.
115. Frederiksen H, Gotssche H, Harboe N, et al. Primary familial amyloidosis with severe amyloid heart disease. Am J Med 1962;33:328-48.
116. Hesse A, Altland K, Linke RP, et al. Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant. Br Heart J 1993;70:111-15.
117. Eriksson A, Olofsson BO, Eriksson P. Heart valve involvement in familial amyloidosis with polyneuropothy. Pathol Res Pract 1986;181:563-7.
118. Saraiva MJM, Sherman W, Marboe C, et al. Cardiac amyloidosis: report of a patient heterozygous for the transthyretin isoleucine 122 variant. Scand J Immunol 1999;32:341-6.
119. Saraiva MJM, Costa PP. Molecular biology of amyloidogenesis in the transthyretin related a myloidoses. In: Natvig JB, Forre O, Husby G, et al, eds. Amyloid and amyloidosis, 1990. Dordrecht: Kluwer Academic Publishers, 1991:560-74.
120. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucin 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med 1997;336:466-73.
121. Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;27:702-6.
122. Goffin YA, Murdoch W, Cornwell GG III, et al. Microdeposits of amyloid in sclerocalcific heart valves: a histochemical and immunofluorescence study. J Clin Pathol 1983;36:1342-9.
123. Yokota T, Okabayashi H, Ishihara T, et al. Immunohistochemical and pathological characteristics of dystrophic amyloid in surgically excised cardiac valves. Pathol Int 1994;44:182-5.
124. Goffin YA, Rickaert F. Histotographic evidence that amyloid deposits in sclerocalcific heart valves and other chronic lesions of the cardiovascular system are related to old thrombotic material. Virch Arch A Pathol Anat Histopathol 1986;409:61-77.
125. Goffin YA, Gruys E, Sorenson GD, et al. Amyloid deposits in bioprosthetic cardiac valves after long-term implantation in man. A new localization of amyloidosis. Am J Pathol 1984;114:431-42.
126. Mucchiano GI, Cornwell GG III, Westermark P. Senile aortic amyloid. Evidence for two distinct forms of localised deposits. Am J Pathol 1992;140:871-7.
127. Cornwell GG III, Westermark P, Murdoch W, et al. Senile aortic amyloid. A third distinctive type of age-related cardiovascular amyloid. Am J Pathol 1982;108:135-9.
128. Häggqvist B, Näslund J, Sletten K, et al. Medin: an integral fragment of aortic smooth muscle cell-produced lastadherin forms the most common human amyloid. Proc Natl Acad Sci U S A 1999;96:8669-74.
129. Peng S, Westermark GT, Naslund J, et al. Medin and medin-amyloid in ageing inflamed and non-inflamed temporal arteries. J Pathol 2002;196:91-6.
130. Mucchiano GI, Jonasson, Haggqvist B, et al. Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol 2001;115:298-303.
131. Mucchiono GI, Haggqvist B, Sletten K, et al. Apolipoprotein A-I-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001;193:270-5.
132. Yamado T, Kakihara T, Kamishima T, et al. Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Pathol Int 1996;46:797-800.
133. Johnson KH, Sletten K, Hayden DW, et al. Pulmonary vascular amyloidosis in aged dogs. A new form of spontaneously occurring amyloidosis derived from apolipoprotein A1. Am J Pathol 1992;141:1013-19.
134. Ogawa H. Senile cardiac amyloidosis in senescence accelerated mouse (SAM). Jpn Circ J 1988;52:1377-83.
135. Sezer O, Niemöller K, Jakob C, et al. Novel approaches to the treatment of primary amyloidosis. Exp Opin Invest Drugs 2000;9:2343-50.
136. Hall R, Hawkins PN. Cardiac transplantation for AL amyloidosis. BMJ 1994;309:1135-7.
137. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-55.
138. Grazi GL, Cescon M, Salvi F, et al. Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl 2003;9:986-92.
139. Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71:986-92.
140. Kolstoe S, Wood S. Perspectives for drug intervention in amyloid diseases. Curr Drug Targets 2004;5:151-8.
141. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9.
142. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
143. Reyners AK, Hazenberg BP, Reitsma WD, et al. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002;23:157-61.